INmune Bio, Inc.
INMB
$1.98
-$0.03-1.49%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.72% | 9.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.07% | 5.15% | |||
| Operating Income | 18.66% | -4.63% | |||
| Income Before Tax | -151.13% | -5.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -151.13% | -5.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -151.13% | -5.65% | |||
| EBIT | 18.66% | -4.63% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -142.50% | -4.46% | |||
| Normalized Basic EPS | 21.25% | -4.48% | |||
| EPS Diluted | -142.50% | -4.46% | |||
| Normalized Diluted EPS | 21.25% | -4.48% | |||
| Average Basic Shares Outstanding | 3.57% | 1.12% | |||
| Average Diluted Shares Outstanding | 3.57% | 1.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||